Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Informationsteknik |
| Industri | Programvara |
27.2.2024 10:50:14 CET | Monsenso | Company Announcement
Company announcement no. 03-2024
Copenhagen, 2024.02.27
“This message includes inside information”
Monsenso expects the revenue for 2023 to amount to DKK 9.6m and the EBITDA to amount to DKK -1.4m.
Guidance for the year was revenue of DKK 10-11m and EBITDA DKK -3m to -2m.
The expected revenue is at the low end of the guidance interval, whereas the EBITDA is significantly better than previously expected. The revenue has grown 55% year-over-year, which is a result of impressive efforts during 2023.
The revenue expectations for the year 2024 are DKK 11-13m with an EBITDA of -1,5m to -3,0m.
The main goal for 2024 is to increase our revenue. Over the past few years, we have strengthened our digital health platform to meet the requirements necessary for expanding our market presence. Therefore, we expect to invest more in sales and marketing activities in particularly Denmark, the UK and German-speaking countries in 2024.
The annual report for 2023 will be issued on March 6, 2024.
Further information:
Monsenso
CEO
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com
Chairman of the board
Peter Mørch Eriksen
Tel. +45 51 99 66 00
E-mail: Petermorcheriksen@outlook.com
Certified Adviser
Norden CEF A/S
John Norden
E-mail: jn@nordencef.dk
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com